Translation of anticancer efficacy from nonclinical models to the clinic

Area of Science:

• Oncology
• Translational Research
• Preclinical Models

Background:

• Mouse cancer models are crucial for understanding tumor biology.
• Clinical translation of findings from mouse models remains a significant hurdle.
• Limitations exist in accurately capturing human cancer pathophysiology in preclinical settings.

Purpose of the Study:

• To address the challenges in translating mouse cancer model findings to human clinical applications.
• To propose a comprehensive approach for strengthening oncology drug development.
• To identify key factors hindering successful clinical translation.

Main Methods:

• Perspective-based analysis of current limitations in preclinical cancer research.
• Discussion of strategies to improve the translatability of mouse models.
• Emphasis on integrated biomarker strategies and modeling/simulation efforts.

Main Results:

• Identified limitations in capturing human cancer pathophysiology as a primary barrier.
• Highlighted challenges in generating robust and translatable preclinical endpoints.
• Proposed a comprehensive approach to bridge the gap between preclinical findings and clinical outcomes.

Conclusions:

• A comprehensive strategy integrating clinically relevant mouse models, biomarkers, and modeling is essential.
• Addressing pathophysiology capture and endpoint translatability will enhance oncology drug development.
• This approach aims to strengthen the preclinical to clinical translation paradigm in cancer research.